A fourth COVID-19 vaccine could soon be offered to the public in the United States.
AstraZeneca's two-shot vaccine just concluded its third trial and it's been shown to be 79% effective when preventing symptomatic COVID-19 and 100% effective at preventing severe disease and hospitalization.
The company said in a statement that the two-dose vaccine produced constant positive results across all ages and ethnicities, and even showed 80% effectiveness in people over the age of 65.
"These results add to the growing body of evidence that shows this vaccine is well tolerated and highly effective against all severities of COVID-19," said Mene Pangalos, Executive Vice President of AstraZeneca, "We are confident this vaccine can play an important role in protecting millions of people."
The company is now preparing to submit the trial results to the US Food and Drug Administration in hopes of receiving US Emergency Use Authorization, which would allow them to roll out millions of doses to the public.
The CDC has a robust website with all the latest information on the vaccines and can answer any questions you may have. Click here for more information.